Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2006)
An Assessment of Linezolid Utilization in Selected Canadian Provinces
Abstract
BACKGROUND: Linezolid is approved for the treatment of designated infections caused by methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.